普通外文研报

Vicore Pharma Holding AB-KOL webcast key take-aways-06/09/2026

发布日期: 2026-06-09研究机构: Pareto Securities AS报告页数: 1原文语言: 英语证据页码: 1

研报英文原文证据摘录

Vicore Pharma Holding AB

NEWSFLASH | 9 JUN 2026

KOL webcast key take-aways

Following ATS 2026, Vicore hosted a KOL call featuring Dr. Phil Molyneaux, an IPF expert and investigator in the company’s

ongoing phase 2b trial. On a general take, tolerability remains one of the major challenges across the IPF pipeline. In

contrast, Vicore’s has so far demonstrated a very differentiated profile with no GI side effects, the potential of FVC gains

and combinable with existing and emerging therapies. The company expects a futility analysis to be completed by Q4 2026,

that will further reduce the clinical risks. Given buloxibutid’s outstanding tolerability, we expect it to be successful and see

a much lower risk of early trial termination compared to previous failures such as Galapagos's phase 3 trial.

How are the competitors doing in terms of tolerability?

In addition to not showing FVC improvements (slowing of decline at best), inhaled treprostinil (Tyvaso) carries high cough rates of 52% vs.

29% placebo across the Teton-1 and 2 trials, and a 40.5% discontinuation rate in Teton-1 driven primarily by AEs. Nerandomilast

(Jascayd) carries GI side effects, with diarrhea reported in 42% of patients on monotherapy and 62% in combination with nintedanib.

Nalbuphine ER (CORAL Ph2b), on the other hand, showed discontinuation rates of just 5.6% vs. 5.0% on placebo, and is generally well

tolerated, positioning it as potential add-on to current IPF therapies. However, the effect of nalbuphine ER is limited to symptom control

(cough reduction) without disease-modifying (FVC) benefit.

Our question: potential read-across from treprostinil’s phase 3 data to buloxibutid?

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文，不做批量翻译；登录后在阅读器切换中文时才按需翻译。